[Early alterations of adrenergic cardiac function in Parkinson's disease].
BACKGROUND
Myocardial sympathetic (adrenergic) function is significantly affected in patients with idiopathic Parkinson's disease (PD) as is deduced from the cardiac scintigraphy evaluation with 123I-metaiodobenzylguanidine (123I-MIBG).


METHODS
In the present study, 60 patients with PD were studied compared to 17 normal subject without neurological disease. The clinical parameters evaluated were severity of the condition (measured by Hoehn and Yahr Scale), vegetative manifestations, development time and use and type of medication taken. Myocardial adrenergic function was analyzed by imaging with 123I-MIBG. Early (15 min) and delayed (4 h) images of the anterior view were obtained after injection of 123I-MIBG. Qualitative and semiquantitative 123I-MIBG uptake was quantified by calculating a heart-to-mediastinum (H/M) ratio.


RESULTS
We found a significant decrease of H/M ratio in patients with PD as compared with controls (p < 0.01) independently of development time, severity of the condition, use of medication or vegetative manifestations.


CONCLUSIONS
There is an important noradrenergic alteration in PD, that can be detected from early stages and does not exist in other parkinsonisms caused by a different pathogenic mechanism.
Campos
V
V
Servicio de Neurología, Hospital Universitario Virgen de la Victoria, Málaga, Spain. vcampos@activanet.es
Rebollo
A C
AC
Jiménez-Hoyuela
J M
JM
Gómez-Doblas
J J
JJ
Medialdea
P
P
Vila
E
E
Gutiérrez-Hurtado
A
A
D019797:3-Iodobenzylguanidine; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000503:physiopathology*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013564:Sympathetic Nervous System / Q000503:physiopathology*
D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine